Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

Samuel M. Lindner; Christopher B. Fordyce; Anne S. Hellkamp; Yuliya Lokhnygina; Jonathan P. Piccini; Gnter Breithardt; Kenneth W. Mahaffey; Daniel E. Singer; Werner Hacke; Jonathan L. Halperin; Graeme J. Hankey; Scott D. Berkowitz; Christopher C. Nessel; Richard C. Becker; Keith A. A. Fox; Manesh R. Patel; ROCKET AF Investigators

doi:10.1161/CIRCULATIONAHA.116.024666

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Gnter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A. A. Fox, Manesh R. Patel, ROCKET AF Investigators

Research output: Contribution to journal › Letter › peer-review

32 Citations (Scopus)

Original language	English
Pages (from-to)	1001-1003
Number of pages	3
Journal	Circulation
Volume	135
Issue number	10
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.116.024666
Publication status	Published - 7 Mar 2017

Access to Document

10.1161/CIRCULATIONAHA.116.024666

Cite this

Lindner, S. M., Fordyce, C. B., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Breithardt, G., Mahaffey, K. W., Singer, D. E., Hacke, W., Halperin, J. L., Hankey, G. J., Berkowitz, S. D., Nessel, C. C., Becker, R. C., Fox, K. A. A., Patel, M. R., & ROCKET AF Investigators (2017). Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation, 135(10), 1001-1003. https://doi.org/10.1161/CIRCULATIONAHA.116.024666

Lindner, Samuel M. ; Fordyce, Christopher B. ; Hellkamp, Anne S. et al. / Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. In: Circulation. 2017 ; Vol. 135, No. 10. pp. 1001-1003.

@article{de4674cd523046708d5f8aef8a238736,

title = "Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis",

keywords = "atrial fibrillation, renal function, SYSTEMIC EMBOLISM, OUTCOMES",

author = "Lindner, {Samuel M.} and Fordyce, {Christopher B.} and Hellkamp, {Anne S.} and Yuliya Lokhnygina and Piccini, {Jonathan P.} and Gnter Breithardt and Mahaffey, {Kenneth W.} and Singer, {Daniel E.} and Werner Hacke and Halperin, {Jonathan L.} and Hankey, {Graeme J.} and Berkowitz, {Scott D.} and Nessel, {Christopher C.} and Becker, {Richard C.} and Fox, {Keith A. A.} and Patel, {Manesh R.} and {ROCKET AF Investigators}",

year = "2017",

month = mar,

day = "7",

doi = "10.1161/CIRCULATIONAHA.116.024666",

language = "English",

volume = "135",

pages = "1001--1003",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "10",

}

Lindner, SM, Fordyce, CB, Hellkamp, AS, Lokhnygina, Y, Piccini, JP, Breithardt, G, Mahaffey, KW, Singer, DE, Hacke, W, Halperin, JL, Hankey, GJ, Berkowitz, SD, Nessel, CC, Becker, RC, Fox, KAA, Patel, MR & ROCKET AF Investigators 2017, 'Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis', Circulation, vol. 135, no. 10, pp. 1001-1003. https://doi.org/10.1161/CIRCULATIONAHA.116.024666

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. / Lindner, Samuel M.; Fordyce, Christopher B.; Hellkamp, Anne S. et al.
In: Circulation, Vol. 135, No. 10, 07.03.2017, p. 1001-1003.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

AU - Lindner, Samuel M.

AU - Fordyce, Christopher B.

AU - Hellkamp, Anne S.

AU - Lokhnygina, Yuliya

AU - Piccini, Jonathan P.

AU - Breithardt, Gnter

AU - Mahaffey, Kenneth W.

AU - Singer, Daniel E.

AU - Hacke, Werner

AU - Halperin, Jonathan L.

AU - Hankey, Graeme J.

AU - Berkowitz, Scott D.

AU - Nessel, Christopher C.

AU - Becker, Richard C.

AU - Fox, Keith A. A.

AU - Patel, Manesh R.

AU - ROCKET AF Investigators

PY - 2017/3/7

Y1 - 2017/3/7

KW - atrial fibrillation

KW - renal function

KW - SYSTEMIC EMBOLISM

KW - OUTCOMES

U2 - 10.1161/CIRCULATIONAHA.116.024666

DO - 10.1161/CIRCULATIONAHA.116.024666

M3 - Letter

C2 - 28264892

SN - 0009-7322

VL - 135

SP - 1001

EP - 1003

JO - Circulation

JF - Circulation

IS - 10

ER -

Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G et al. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 2017 Mar 7;135(10):1001-1003. doi: 10.1161/CIRCULATIONAHA.116.024666